Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 59Colorectal Neoplasms 45Rectal Neoplasms 35Stomach Neoplasms 27Pancreatic Neoplasms 27Neoplasm Metastasis 24Neoplasms 19Colonic Neoplasms 18Triple Negative Breast Neoplasms 7Esophageal Neoplasms 6Adenocarcinoma 6Liver Neoplasms 5Brain Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Unknown Primary 2Melanoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma 2Breast Neoplasms, Male 2

Interventions

Octreotide 3Irinotecan 2cabazitaxel 1XRP6258 1Theophylline 1Surveys and Questionnaires 1Sugars 1Prednisone 1PHY 906 1Leucovorin 1Lapatinib 1Fluorouracil 1Erlotinib Hydrochloride 1Endoscopy 1Drugs, Investigational 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diarrhea × Capecitabine × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡